2022 October - Stanford Cancer Institute (SCI) Innovation Awards-- Call for PROPOSALS

AWARD CATEGORIES:

• Stanford Cancer Institute Nodal Grant Awards ($50,000) 
• Stanford Cancer Institute Innovation Awards ($50,000)
  • Single PI
  • Multi PI collaboration leading to multi PI peer-reviewed funding
• Stanford Cancer Institute Pancreatic Cancer Innovation Awards ($50,000)
• Stanford Women's Cancer Center Innovation Awards ($50,000)
• Shmunis Family Innovation Awards in Cancer Therapeutics ($50,000)

Timeline:

RFA Announced:  April 15, 2022
Proposal submission deadline: June 10, 2022   
Notification of Selection: August 1, 2022
Funding Period:  October 1, 2022 – September 30, 2023

Program priorities 

• Bold and creative research projects
• Research related to health disparities
• Multi-disciplinary collaboration, including collaborations involving Stanford faculty beyond the School of Medicine or inter-programmatic collaborations across the seven SCI research programs
• Potential to lead (or is already leading) to an investigator-initiated clinical trial
• Plans for submission of an external peer reviewed (preferably NCI) application

Eligibility: 

Faculty members of the SCI or of the Stanford University community with PI Status.

Instructors may not serve as PI, but must be partnered with an SCI member with PI status. 

Apply/learn More

• Call for Seed Grant Proposals

We are excited to announce a funding opportunity as part of the 2022 Diversity in AI Research for Cancer Molecular Imaging Conference made possible by the generous support by the Stanford Department of Radiology, Stanford Cancer Institute and Stanford Center for Artificial Intelligence and Medical Imaging.

We plan to support two seed grants of $10,000 each for interdisciplinary research projects on Diversity in Artificial Intelligence Research in Cancer Molecular Imaging. Applications require a Stanford PI or Co-PI, at least one Stanford Radiology faculty on the project team, and to foster trans-institutional collaborations, must include at least one Co-Investigator from another institution. The budget will be managed by the Stanford investigator. Seed grand awardees will be invited to present our project at the conference. 

Proposals should focus on at least one of the following priority areas, as they relate to AI in Cancer Molecular Imaging:

1. Racial Diversity in STEM
2. Women in STEM
3. Global Health

Proposals are due May 20, 2022 at 11:59pm PT

Submit Proposal

Proposal Format (1-page, PDF):

• Title
• PI, Co-PI (if applicable), Co-Investigators - see above for team requirements
• Background and problem statement; core research idea; research plan; expected outcomes
• Relevance to diversity in STEM (2-3 sentences)
• Requested funding and informal budget sketch ($10,000 max)
• References (not included in 1-page max)

• Full description here: https://www.cureswithinreach.org/wp-content/uploads/2022/03/CWR-US-Based-Clinical-Repurposing-Trials-to-Address-DEI.pdf

•  
• Description / Background
• Proposals are submitted on the Cures Within Reach CureAccelerator online platform. Sign up as a Researcher or Clinician at https://app.cureaccelerator.org/registration or log into an existing CureAccelerator account at https://app.cureaccelerator.org/home to submit. Additional Proposal submission instructions can be downloaded at this link: http://bit.ly/cwrclinicalrfp.

• This Request for Proposals (RFP) from Cures Within Reach (CWR) is seeking clinical repurposing trials from US-based Principal Investigators (PIs) to address Diversity, Equity and Inclusion in clinical research. Clinical trials utilizing telehealth or other remote strategies are encouraged to apply.
• Eligible submissions must EITHER:
  Be led by a US-based underrepresented racial / ethnic minority PI (as defined by the NIH;
• Section A in https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html ) OR
• Address rare disease racial / ethnic health disparities in communities of color as defined by the NIH (see https://www.nimhd.nih.gov/about/overview), led by a PI of any racial / ethnic background
• AND
• Be interventional clinical trials using repurposed therapies, including drugs, devices, nutraceuticals and diagnostics, that are already approved or generally recognized as safe by the US Food and Drug Administration, the European Medicines Agency or other regulatory agency
• Be conducted at a US-based accredited academic, nonprofit and governmental research institutions and/or health systems significantly involved with medical research, where good scientific research and clinical practices can be assured
•  
• CWR is accepting clinical research budgets of up to $70,000.00 for this funding opportunity, which includes the required 20% Institutional Match.
• Any health disparities submissions for this RFP must include ideas and/or plans for engagement / collaborations with community-based organizations to engage communities of color in the clinical trial. CWR will provide up to $15,000 in additional financial support for community engagement, with at least $5,000 required for community engagement. CWR recommends a range of $7,500 - $15,000. Ideas for possible community engagement must be included in the Research Description section of the proposal and do not count towards the suggested word length of 750 words. Community-based organizations are already engaged with and trusted by communities of color, and may include health-related organizations (i.e., community health centers), social services-related organizations (i.e., food banks) or other organizations (i.e., religious groups). Community engagement ideas do not need specific details at the proposal stage, and proposals will not be scored on community engagement in the review process.
•  
• Clinical repurposing trials led by an underrepresented racial / ethnic minority PI may, but are not required to, focus on health disparities. CWR is also interested in promoting Diversity, Equity and Inclusion in biomedical clinical research by 1) supporting the careers of and 2) closing the NIH funding gap for underrepresented racial / ethnic groups through funding for clinical repurposing trials led by minority PIs.
• CWR is seeking health disparities projects that – in addition to creating positive patient impact via clinical data – will help to:
• improve the health and healthcare of communities of color, and/or
• reduce the fear and mistrust of clinical trial participation, and/or
• engage and educate prospective participants about clinical repurposing trials using already approved therapies

• Exploration – Hypothesis Development Award (EHDA)
• Early Investigator Research Award (EIRA)
• Physician Research Award (PRA)
• Translational Science Award (TSA)
• Health Disparity Research Award (HDRA)
• Idea Development Award (IDA)
• Data Science Award (DSA)

Program Announcement/Instructions

• Concept Award (CA)
• Idea Development Award (IDA)
• Postdoctoral and Clinical Fellowship Award (PCFA)
• Translational Research Partnership Award (TRPA)

Program Announcement/Instructions

• Behavioral Health Science Award (BHSA)
• Career Development Award (CDA) – Fellow Option
• Career Development Award (CDA) – Virtual Cancer Center Scholar Option
• Translational Team Science Award (TTSA)
• Convergent Science Cancer Consortium Development Award (CSCCDA)
• Idea Award (IA)
• Impact Award (IPA)

Program Announcement/Instructions

• Concept Award (CA)
• Idea Development Award (IDA)
• Resource and Community Development Award (RCDA)

Program Announcement/Instructions

• Career Development Award (CDA)
• Concept Award (CA)
• Clinical Translational Research Partnership Award (CTRPA)
• Idea Development Award (IDA)
• Investigator-Initiated Translational Research Award (IITRA)

Program Announcement/Instructions

• Idea Development Award (IDA)
• Translational Research Partnership Award (TRPA)

Program Announcement/Instructions

The American Cancer Society (ACS) announced an exciting partnership with the Lisa Dean Moseley Foundation to create a research consortium to advance the translation of cancer stem cell discoveries and accelerate patient impact. This new project will be a six-year initiative supporting the peer-reviewed work of up to 15 Principal Investigators, which includes a Consortium Lead Award, an Interdisciplinary Team Award, and numerous Research Scholar Grants (for independent investigators at all career ranks and levels of extramural funding), Clinician Scientist Development Grants, and Postdoctoral Fellowships. ACS welcomes innovative cancer stem cell ideas from collaboratively minded investigators, including those with current ACS funding, at eligible institutions across the United States and U.S. territories.

More details about the diverse funding mechanisms and the associated collaborative learning community can be found on cancer.org. ACS is hosting an informational webinar with Q&A on January 31^st from 12-1pm EST to provide ample time for applicants to prepare for LOIs due in March (select mechanisms only) and for the June 1, 2022 application deadline.

https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant.html

https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/rfa-cancer-stem-cell-consortium.html

The American Cancer Society has announced a new RFA focused on testing innovative solutions to improve cancer screening and early detection. This could entail better implementing existing screening tests, adapting current tests and technologies, or developing new tools.

Funds will support at least 2 Interdisciplinary Team Awards, 7 Research Scholar Grants, and 2 Clinician-Scientist Development Grants.

An informational webinar and Q&A will be held on May 16 from 12-1 EST. Register here: 
https://us06web.zoom.us/meeting/register/tZcsduCqrTwjHdzFh80tuvxgeI0ROGLcvJnQ

For full details on eligibility, scientific scope, application deadlines, etc., please visit https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/rfa-screening-research-priority-area.html

Applications Open in proposalCENTRAL: 

• Interdisciplinary Team Award LOI: May 2022
• RSG and CSDG: May 2022

Interactive Webinar to Learn More: 
May 16, from 12 to 1 PM EST (Webinar will be recorded and available upon request.)
Register for the webinar. 

Team LOI Due Date: June 15, 2022 

Application Deadline (all mechanisms): August 1, 2022

Application Review: October 2022

Award Notification: December 2022

Grant Activation: January 2023

Funds Available for Awards: Funds will support at least 2 Interdisciplinary Team Awards, 7 Research Scholar Grants, and 2 Clinician-Scientist Development Grants. 

Program Contact: Kim Clarke at kimberly.clarke@cancer.org

Endeavor Award 2023 RFP Opens May 19 

The Mark Foundation Endeavor Awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are $3 million grants disbursed over a three-year term.

Webinar registration is now open! Sign up to learn more about the Endeavor Program, including an overview, eligibility requirements, the application process, and a Q&A period. Attendance at the webinar is optional – all information presented will be posted on the Endeavor Award website.  All three webinar sessions will cover the same information, so we request that you register for one session only.

Be inspired! Read about the 2022 Endeavor Award teams tackling some of the toughest challenges in cancer research here.

Eligibility

Institutional Eligibility:

• Open to non-profit academic/research institutions.
• Open to institutions worldwide.
• Teams may comprise investigators from a single institutions or multiple institutions.
• There is no requirement to include a US-based institution as part of the team.
• Institutions may submit more than one application.

Investigator Eligibility:

• There are no restrictions on citizenship or geography.
• Applicants must have an independent faculty research appointment (tenure-track or equivalent) at a non-profit academic institution.
• Investigators may be co-PI or collaborator on more than one proposal but may only serve as Principal Investigator on one proposal.
• Investigators who are currently a co-PI on an Endeavor team are permitted to apply as co-PI or collaborator on a new application.

Project Eligibility:

• Basic, translational, and clinical projects are eligible.
• The project must seek to address an overarching, urgent scientific question.
• Sub-projects should be designed to elucidate various aspects of the overarching question, theme, or focus.
• The output of the individual team members (data, samples, hypotheses, compounds, etc.) must be integrated and/or shared in a way that makes the impact of the project as a whole larger than the sum of its parts.
• Proposed projects must not be supported by other sources of funding. Finalists will be asked to discuss any potential overlap with other current or pending awards.

Team Composition:

• Teams must be composed of one PI, and between 2-8 co-PIs (see “Team Roles” section for definitions).
• Inter-institutional collaborations are permitted and encouraged.
• Teams are encouraged to consider diversity in terms of discipline, seniority, gender, race, ethnicity, and any other parameters that will enhance the team’s ability to approach challenging problems from fresh perspectives.
• The Mark Foundation for Cancer Research does not discriminate on the basis of race, color, religion, national origin, sex, gender identity, sexual orientation, age, disability, or any other legally protected characteristics.

Program Overview

The Stanford Cancer Center Clinical Innovation Fund (CIF) seeks to drive, and fund innovative projects designed to elevate the quality of care, enhance the patient/provider experience, and expand Stanford Cancer Center outreach & growth, as aligned with Stanford Cancer Transformation.

CIF accepts proposal submissions twice a year on: January 31st and July 31^st

Proposals should be designed to:

• Enhance the patient & provider experience
• Improve quality of care in outpatient/inpatient settings
• Promote clinical outreach and Cancer Center volume growth
• Increase value of care by reducing costs while improving patient care
• Promote physician, nursing, and APP education around cancer and overall care delivery
•  
• When preparing your proposal for submission, it is important to keep the following items in mind:
• Eligibility is open to Cancer Service Line (CSL) providers (MD & APP), nursing staff (coordinators, clinical), and administrators/managers. Non-CSL affiliated personnel who are interested in submitting a CIF proposal must align their project with a CSL member or affiliate as an active PI or Co-PI for the proposal to be considered for funding.
• Total project budget for the proposal cannot exceed $150,000. 
• Total project salaries for faculty and benefits cannot exceed 10% of the total budget requested.
• Supplemental information is encouraged any format (.doc, .ppt , .pdf, .jpeg, .mp4, .wav, etc.). Additional supplements can be added to an application that has already been submitted, provided the materials are received before 11:59pm PT on the date of the deadline.

• All proposals should be submitted on the CIF Application form via email to the Clinical Innovation Fund.  Directions on how to complete the application can be found here. After a submission cycle closes, each proposal undergoes several rounds of review to ensure Cancer Transformation goals alignment, innovative potential, and feasibility. Requestors can expect to receive a decision response approximately two months after the funding deadlines.

• Extension Requests:
• PIs with CIF awarded projects can request for an extension with the following in mind:
• Complete this form to request for an extension and submit to the Clinical Innovation Fund.
• Requests should be submitted two months before the project end date to provide CIF leadership time to review.
• Requests for extensions submitted after project end date will be at risk of losing access to any remaining funds in budget. 
• Extensions can be requested for up to 1 additional year.

• Forms
• CIF application
• Directions on how to complete the application
• Request for Extension
• Request for Change in Budget

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible.

Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible. Learn more about these opportunities here.

Cancer Moonshot - UPDATED Funding Opportunities link